Clinical Trial Search

Primary: Number of Genes Upregulated or Downregulated as Assessed by RNA Sequencing (Older Group, Retinol Versus Placebo) — 23; 21 genes

Primary: Reduction of Bruising — 3.74; 4.50 cm squared

Primary: Cochin Hand Functional Scale — 19.24 units on a scale

Primary: Median VAS Improvement Score as Assessed by Blinded Physician Reviewers — 1.5 units on a scale — p=<0.0001

Primary: Mean Change on Busso Hand Volume Severity Scale (BHVSS), by Hand — 2.54; 2.44; 1.72; 2.44 units on a scale — p=< 0.0001

Primary: The Efficacy of Restylane Vital on Skin Structure Compared to no Treatment Using a Validated Scale. — 0.85; 2.17 units on a scale

Primary: Mean Change on Merz Hand Grading Scale (MHGS), by Hand — 2.6; 2.6; 1.5; 2.6 units on a scale — p=<0.0001

Primary: Number of Participants With X-ray of Either Hand With Bone Obscuration at Month 1 — 0; 0 participants

Primary: Percent Reduction in the Number of Hand Lentigines as Assessed by Blinded Reviewers.

Primary: Proportion of Subjects With Device-and/or Injection-related Severe Treatment-emergent Adverse Events (TEAEs) in the Grade 4 Hands Group Versus the Grade 2-3 Hands Group…

Primary: Fold Change in Long Chain Fatty Acids — 1; 0.76 Fold Change in long chain fatty acids

Primary: CRM Performance During First Sim Scenario Assessed by Ottawa Global Rating Scale (GRS) — -0.299 Pearson correlation coefficient — p=0.039

Primary: Hydration Level — 53.19; 46.75 AU (arbitrary unit) — p=<0.05

Primary: The Change From Baseline to 30 Days After the Last Treatment in the Number of Senile Purpura Lesions — -3.55; -.35 number of purpuric lesions

Primary: Change From Baseline in Ra (a dermaTOP Parameter), of Test Product Treated Versus (vs.) Untreated Side at Day 29 — -1.90; -0.12 Micro meter (µm) — p=0.0638

Primary: Primary Objective Foam Sanitizer User Touch and Feel Experience — 53.21; 39.62; 61.21; 49.73 score on a scale

Primary: Australian Canadian OA Hand Index (AUSCAN) — 3.3; 1.3; 2.0; 1.6 score on a scale

Primary: Responder Rate Using Validated Hand Grading Scale — 73; 18; 12; 67 Participants — p=<0.0001

Primary: The Within-subject Difference in VAS Score (Restylane Skinboosters Vital Lidocaine- Restylane Vital) at End of Injection (T0). — 32.5; 46.9 score on a scale — p=<0.0001

Primary: Skin Aging Measured With the Photonumeric Scale. — 21.25; 21.36; 21.21; 21.03 Units on a scale

Primary: Investigator Global Assessment — 1.0; 1.1 units on a scale

Primary: Primary Outcome Measure for Efficacy (IGA) — 2.33; 2.20; 2.43; 2 score on a scale

Primary: Difference in Basal Layer Keratinocytes Positive for Both Ki67 and Thymine Dimers — 21.5; 14.7 positive cells/1000 basal layer cells

Primary: Carotid-femoral Pulse Wave Velocity (CFPWV) — 831.3; 785.1; 538.0; 839.6 cm/sec

Primary: Factors Associated With Eaton Classification of Trapeziometacarpal Arthrosis: Age — 61; 66; 75 Years

Primary: Muscle Satellite Cells — 3.2; 3.2; 4.0; 3.8 Number of Pax7+ cells/muscle fiber

Primary: Estimate Cardiovascular Efficiency After Aerobic Exercise — 24.01; 31.2; 32.3 ml/kg(min) — p=.001

Primary: Cutaneous Blood Flow Response to Local Heating of the Skin. — 68; 70 percent change in mean skin blood flow

Primary: Skeletal Muscle Capillarization — 0.4; 0.2 capillaries per muscle fiber — p=0.27

Primary: Number of Genes With Significant Change in Gene Transcription — 188; 45 genes